TY - JOUR
T1 - Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia
AU - Pinder, M.
AU - Reece, W. H H
AU - Plebanski, M.
AU - Akinwunmi, P.
AU - Flanagan, K. L.
AU - Lee, E. A M
AU - Doherty, T.
AU - Milligan, P.
AU - Jaye, A.
AU - Tornieporth, N.
AU - Ballou, R.
AU - Mcadam, K. P M J
AU - Cohen, J.
AU - Hill, A. V S
PY - 2004/2
Y1 - 2004/2
N2 - Vaccination of malaria-naive humans with recombinant RTS,S/AS02, which includes the C-terminus of the circumsporozoite protein (CS), has been shown to induce strong T cell responses to both the whole protein antigen and to peptides from CS. Here we show that strong T cell responses were also observed in a semi-immune population in The Gambia, West Africa. In a Phase I study, 20 adult male volunteers, lifelong residents in a malaria-endemic region, were given three doses of RTS,S/AS02 at 0, 1 and 6 months. Responses to RTS,S, hepatitis B surface antigen and peptides from CS were tested using lymphocyte proliferation, interferon (IFN)-γ production in microcultures, and IFN-γ ex vivo and cultured ELISPOT, before and after vaccination. Cytotoxic responses were tested only after vaccination and none were detected. Before vaccination, the majority of the volunteers (15/20) had detectable responses in at least one of the tests. After vaccination, responses increased in all assays except cytotoxicity. The increase was most marked for proliferation; all donors responded to RTS,S after the third dose and all except one donor responded to at least one peptide after the second or third dose. There was a lack of close association of peptide responses detected by the different assays, although in microcultures IFN-γ responses were found only when proliferative responses were high, and responses by cultured ELISPOT and proliferation were found together more frequently after vaccination. We have therefore identified several peptide-specific T cell responses induced by RTS,S/AS02 which provides a mechanism to investigate potentially protective immune responses in the field.
AB - Vaccination of malaria-naive humans with recombinant RTS,S/AS02, which includes the C-terminus of the circumsporozoite protein (CS), has been shown to induce strong T cell responses to both the whole protein antigen and to peptides from CS. Here we show that strong T cell responses were also observed in a semi-immune population in The Gambia, West Africa. In a Phase I study, 20 adult male volunteers, lifelong residents in a malaria-endemic region, were given three doses of RTS,S/AS02 at 0, 1 and 6 months. Responses to RTS,S, hepatitis B surface antigen and peptides from CS were tested using lymphocyte proliferation, interferon (IFN)-γ production in microcultures, and IFN-γ ex vivo and cultured ELISPOT, before and after vaccination. Cytotoxic responses were tested only after vaccination and none were detected. Before vaccination, the majority of the volunteers (15/20) had detectable responses in at least one of the tests. After vaccination, responses increased in all assays except cytotoxicity. The increase was most marked for proliferation; all donors responded to RTS,S after the third dose and all except one donor responded to at least one peptide after the second or third dose. There was a lack of close association of peptide responses detected by the different assays, although in microcultures IFN-γ responses were found only when proliferative responses were high, and responses by cultured ELISPOT and proliferation were found together more frequently after vaccination. We have therefore identified several peptide-specific T cell responses induced by RTS,S/AS02 which provides a mechanism to investigate potentially protective immune responses in the field.
KW - Cell-mediated
KW - Circumsporozoite
KW - ELISPOT
KW - Immunity
KW - Plasmodium falciparum vaccine
UR - http://www.scopus.com/inward/record.url?scp=10744225844&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2249.2004.02371.x
DO - 10.1111/j.1365-2249.2004.02371.x
M3 - Article
C2 - 14738458
AN - SCOPUS:10744225844
SN - 0009-9104
VL - 135
SP - 286
EP - 293
JO - Clinical & Experimental Immunology
JF - Clinical & Experimental Immunology
IS - 2
ER -